14 results about "Artificial tears" patented technology

The invention relates to the technical field of medical preparations, in particular to moisturizing and repairing type artificial tear as well as a preparation method and application thereof. Comprising the following steps: preparing effective components including high-molecular-weight polydeoxyribonucleotide and hyaluronic acid or a salt thereof into a homogeneous-phase stable composite solution, sterilizing, filtering, and aseptically packaging, the artificial tear formed by selecting high-molecular-weight polydeoxyribonucleotide and high-molecular-weight sodium hyaluronate as effective components has a relatively good repairing effect on tissues, can form long-term moisturizing and lubrication on ocular surfaces, is suitable for treating xerophthalmia, repairing cornea, relieving inflammatory response and the like, and has a good application prospect. Important market values and clinical application prospects are realized.

The present invention relates to ophthalmic formulations comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate polyethylene glycol and artificial tear solutions, and to processes for preparing said ophthalmic formulations.

1. The name of this design product: artificial tear duct. 2. Purpose of this design product: used as an artificial tear duct. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the key points of the design: Main view of Design 1. 5. Designate Design 1 as the base design. 6. Other situations that need to be explained Other explanations: The double-dotted lines on the main view, rear view, left view and right view of Design 1 of this application indicate that the middle length on both sides of the double-dotted lines are omitted; the dotted lines in Design 2 of this application indicate the inserted rod-shaped object, which is a non-transparent solid rod, and the other parts are transparent tubular objects.

The invention discloses an intelligent dry-eye-preventing contact lens for monitoring and adjusting tears in real time. The intelligent dry-eye-preventing contact lens comprises an external radio frequency transmitter, a flexible circuit module and a flexible substrate with a detection bin and a medicine bin, the radio frequency transmitter transmits 100-200MHz radio frequency electromagnetic waves, the flexible circuit module is embedded into the flexible substrate and is integrated with a coupling coil L1, an MCU, a Bluetooth module, a sensing module and a medicine discharging module, wireless energy supply is achieved through electromagnetic induction, the sensing module collects tear data, and the medicine discharging module controls the medicine bin to release artificial tears; the flexible substrate integrates the detection bin and the medicine bin, and the opening of the medicine bin is provided with a tridecanoic acid packaging layer. Closed-loop management of real-time tear monitoring and accurate artificial tear release under wireless energy supply is achieved, a battery is not needed, the system is lighter, thinner and safer, remote monitoring is facilitated through real-time data feedback, xerophthalmia is effectively prevented and intervened through accurate drug release, and the technical blank of dynamic tear management and contact lens integrated diagnosis and treatment is filled up.

The invention relates to the technical field of medical instruments, in particular to an atomization device for xerophthalmia treatment, which comprises a control box and a control panel, the control panel is mounted on the outer surface of the control box, a guide mechanism is arranged on the control box, a connecting frame is connected to the guide mechanism, and the guide mechanism is used for guiding liquid medicine into the connecting frame. An atomizer and eyeshades are installed on the connecting frame, the atomizer is used for atomizing liquid medicine and discharging the liquid medicine into the eyeshades, silica gel rings are connected to the eyeshades, and a connecting belt is connected between the two eyeshades. A plurality of second butt joint pipes, a control mechanism (comprising a round block with a channel and a knob frame) and a reset mechanism (comprising a spring, a lifting frame and a limiting rod) are arranged in the control box, so that liquid medicine (such as artificial tears, anti-inflammatory drugs, repair factors and the like) with different functions can be selected and automatically switched according to needs in a treatment process; treatment interruption or manual liquid medicine replacement is not needed, the risk of cross contamination is effectively avoided, and treatment compliance and clinical efficiency are improved.

This application relates to an artificial tear solution and a method for characterizing the protein removal effect of contact lens solution. The artificial tear solution comprises the following components: PBS buffer, lysozyme, sodium hyaluronate, and sodium formate. This invention effectively prevents protein denaturation and improves the stability of the artificial tear solution by adding sodium formate to a conventional artificial tear solution. The addition of sodium hyaluronate makes the protein more difficult to wash off, thereby effectively improving the adhesion of proteins to RGP lenses. Furthermore, the drying process further fixes the protein, thus enabling a more accurate characterization of the protein removal effect of the contact lens solution.

The present invention relates to ophthalmic compositions in the form of oil-in-water (O / W) nano-emulsions, and which mainly comprise propylene glycol and sodium hyaluronate. The invention also relates to preparation methods and uses of the artificial tear compositions.

The invention discloses a water-soluble cellulose derivative-silk fibroin artificial tear with the characteristics of long-acting retention and no irritation and a preparation method thereof. The artificial tear comprises a water-soluble cellulose derivative, silk fibroin, an osmotic pressure regulator, a pH regulator and water. After the water-soluble cellulose derivative is dissolved, a transparent viscous colloid can be formed, a protective film can be formed on the ocular surface, a tear film is stabilized, tear evaporation is delayed, friction is reduced, and dryness and foreign body sensation are rapidly relieved. The polar group of the silk fibroin and the silk fibroin form a stable network through a hydrogen bond, eyelid shearing and tear erosion are resisted, the bioavailability of the silk fibroin is improved, and the silk fibroin has the effects of resisting inflammation and promoting corneal epithelium repair. The osmotic pressure regulator and the pH regulator are cooperated, so that the osmotic pressure and the pH value of the artificial tear approach to those of human tears, the ocular surface is prevented from being stimulated, and the medication comfort and compliance are improved. The artificial tear can quickly relieve the dry eye symptom, realizes long-acting cornea repair, and provides a new strategy for development of a high-efficiency long-acting eye drug delivery system.

The invention provides a novel artificial tear containing recombinant human lysozyme, the novel artificial tear comprises a main component and an auxiliary material, the main component is recombinant human lysozyme, and based on the total mass of the novel artificial tear, the content of the recombinant human lysozyme is greater than or equal to 0.015% and less than 0.075%. The novel artificial tear contains recombinant human lysozyme with lower concentration and has better repairing and anti-inflammatory effects, and compared with the high-concentration artificial tear and the low-concentration artificial tear, the novel artificial tear has more obvious effects of increasing tear secretion, promoting cornea repairing and resisting inflammation. The raw material of the recombinant human lysozyme is derived from the recombinant human lysozyme stock solution, and the pH and osmotic pressure molar concentration value adjustment is not needed in the artificial tear preparation process, so that the large-scale production process can be greatly simplified, and the large-scale production stability is improved.

The invention discloses an ophthalmic nanoemulsion preparation for treating immune xerophthalmia and a preparation method of the ophthalmic nanoemulsion preparation. The ophthalmic nanoemulsion preparation comprises a nanoemulsion inner core loaded with tacrolimus or cyclosporin A, a tear-imitated protein composite layer fixed on an oil-water interface through an amido bond, and surface-modified hyaluronic acid oligosaccharide. Wherein the protein composite layer is formed by covalent crosslinking of lysozyme and lactoferrin according to an optimized molar ratio of 1: (0.8-1.2), and hyaluronic acid is activated by EDC / NHS and then is connected with protein epsilon-amino through an amido bond. The preparation has three breakthrough effects: the first-level release rate constant k of the medicine in artificial tears is less than or equal to 0.25 h <-1 >, and the medicine effect lasts for 8-12 hours; the cornea residence time reaches 4.8 hours or above, and the cornea depends on specific binding of a charge neutral surface and mucoprotein; the activity retention rate of the lysozyme is greater than or equal to 85%, and the HET-CAM irritation score is less than or equal to 0.8, so that the treatment safety and the biocompatibility are remarkably improved. And finally, the core advantage that the ocular surface immune response can be synchronously inhibited and the microenvironment can be repaired by administration for 1-2 times every day is achieved.

The invention relates to a set system for a lacrimal passage plasty operation, and aims to simplify an operation process and relieve pain and tissue damage of a patient. The system comprises a lacrimal ductile lacrimal passage endoscope system, a lacrimal passage forming system, an artificial lacrimal duct system and a programmable intelligent center control system. Wherein the lacrimal ductule lacrimal passage endoscope system is composed of an endoscope with a three-channel pipeline, a handle and a main machine, a flushing and sucking channel is a soft channel, and the section of the flushing and sucking channel is enlarged after water is injected; the lacrimal passage forming system comprises a sacculus pushing-out, inflating and pulling-out device, the sacculus is expanded after being injected with water, so that the narrow part of the lacrimal passage can be expanded, and antennae are arranged on the wall; the artificial lacrimal duct system is a double-probe hose device; the programmable intelligent central control system comprises a plurality of sensors and control devices. The system is suitable for an ophthalmology department operating room, through cooperation of all the devices, the narrow portion of the lacrimal passage can be effectively expanded, exudates and fiber strips can be effectively removed, the artificial lacrimal duct is used for supporting the lacrimal passage to prevent secondary adhesion, regular flushing and massage after operation are conducted, the artificial lacrimal duct is taken out for observation of the curative effect after three months or one year, and the effect of the lacrimal passage forming operation and the patient experience are overall improved.

An oxygen-permeable contact lens comprises a contact lens body, the contact lens body is provided with a convex-arc-shaped outer lens face and a concave-arc-shaped inner lens face located on the opposite side of the outer lens face, and the contact lens body is provided with at least one oxygen-permeable hole which linearly penetrates through the outer lens face and the inner lens face through laser. The air permeability and the oxygen permeation rate of the contact lens are increased by utilizing the oxygen permeation holes, so that when the contact lens is worn, eyeballs can obtain oxygen through the oxygen permeation holes in time, the circulation effect of tears and moisture is improved, uncomfortable symptoms such as eye dryness, stabbing pain or foreign body sensation are greatly reduced, and the wearing comfort is further improved; in addition, eye drops or artificial tears can be used, an eyeball wetting effect can be really achieved through the oxygen permeation holes, and the eye drops or the artificial tears have the convenience of relieving the eyeballs.

The invention relates to the technical field of ophthalmic medicine preparations, in particular to artificial tear simulating a tear film multilayer structure and preparation and application thereof. The artificial tear provided by the invention is prepared from the following components in percentage by mass: 3.0 to 10.0 percent of a structure simulation agent, 0 to 8.0 percent of grease, 0.5 to 2.0 percent of an auxiliary agent and 80.0 to 96.5 percent of PBS (Phosphate Buffer Solution). According to the artificial tear provided by the invention, by simulating the functions of a lipid layer, a water layer and a mucus layer of a tear film, the eye condition is improved from multiple dimensions, the hydrophobic part prevents evaporation and can reduce tear loss and relieve dryness, the hydrophilic part simulates the water layer to supplement moisture, and the synergistic effect of the hydrophilic and hydrophobic structures can repair the integrity of the tear film and prolong the stabilizing time of the tear film; the lubricating effect of interlayer slippage directly relieves discomfort such as foreign body sensation and burning sensation caused by eye friction, and finally relieving of the dry eye symptom, repairing of a tear film structure and long-term maintaining of the wet and lubricating state of the eye surface are achieved.

The application discloses an eye nanoemulsion preparation for treating immune dry eye and a preparation method thereof, and the preparation comprises a nanoemulsion inner core loaded with tacrolimus or cyclosporine A, a simulated tear protein composite layer fixed on an oil-water interface through an amide bond, and surface modified hyaluronic acid oligosaccharide. The protein composite layer is covalently crosslinked by lysozyme and lactoferrin at an optimized molar ratio of 1:(0.8-1.2), and the hyaluronic acid is connected to the epsilon-amino group of the protein through an amide bond after EDC / NHS activation. The preparation achieves three breakthrough effects: the drug first-order release rate constant k is less than or equal to 0.25 h ‑1 in artificial tears, the drug efficacy lasts for 8-12 hours, the corneal retention time is more than 4.8 hours, the specific binding of the charge-neutral surface and mucin is relied on, the lysozyme activity retention rate is greater than or equal to 85%, and the HET-CAM irritation score is less than or equal to 0.8, thereby significantly improving the treatment safety and biocompatibility. Finally, the core advantage that the eye surface immune response and the microenvironment repair can be simultaneously inhibited through 1-2 times of daily administration is achieved.